Assertio Holdings (ASRT) EPS (Weighted Average and Diluted) (2019 - 2026)
Assertio Holdings' (ASRT) quarterly EPS (Weighted Average and Diluted) came in at -$2.93 in Q1 2026, down 38.21% year-on-year from -$4.74 in Q1 2025, and up 35.6% quarter-over-quarter from -$4.55 in Q4 2025.
Assertio Holdings (ASRT) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed EPS (Weighted Average and Diluted) across 8 years of filings, most recently posting -$2.93 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$2.93, down 38.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.54 (down 37.84% YoY), and the FY2025 annual result was -$4.74, down 39.41% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$2.93 for Q1 2026 at Assertio Holdings, up from -$4.55 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.61 in Q4 2022 to a low of -$4.55 in Q4 2025.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.05 (2024), against an average of -$0.86.
- Across the five-year window, EPS (Weighted Average and Diluted) jumped 1363.64% in 2022 and sank 4375.0% in 2023, its largest moves.
- Assertio Holdings' EPS (Weighted Average and Diluted) stood at $1.61 in 2022, then tumbled by 119.88% to -$0.32 in 2023, then slumped by 925.0% to -$3.28 in 2024, then tumbled by 38.72% to -$4.55 in 2025, then soared by 35.6% to -$2.93 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$2.93 (Q1 2026), -$4.55 (Q4 2025), and $0.11 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn | -2.93 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.93 |
| Dec 31, 2025 | -4.55 |
| Sep 30, 2025 | 0.11 |
| Jun 30, 2025 | -0.17 |
| Mar 31, 2025 | -2.12 |
| Dec 31, 2024 | -3.28 |
| Sep 30, 2024 | -0.03 |
| Jun 30, 2024 | -0.04 |
| Mar 31, 2024 | -0.05 |
| Dec 31, 2023 | -0.32 |
| Sep 30, 2023 | -3.42 |
| Jun 30, 2023 | 0.13 |
| Mar 31, 2023 | -0.07 |
| Dec 31, 2022 | 1.61 |
| Sep 30, 2022 | 0.08 |
| Jun 30, 2022 | 0.16 |
| Mar 31, 2022 | 0.20 |
| Dec 31, 2021 | 0.11 |
| Sep 30, 2021 | 0.08 |
| Jun 30, 2021 | -0.32 |